相关实验视频
Updated: Jul 4, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
新兴数字技术和方法论与激励措施对2型糖尿病患者的HbA1c的影响:对平行,开放的随机对照试验的研究协议
Shao Zhong1, Jingyi Jiang1, Hongying Liu2
1Department of Endocrinology, First People's Hospital of Kunshan Affiliated With Jiangsu University, Kunshan, 215300, China.
这项研究探讨了2型糖尿病 (T2DM) 的数字干预措施. 它将数字工具与传统护理的激励措施进行比较,旨在改善T2DM患者的HbA1c和自我护理行为.
科学领域:
- 数字健康数字健康
- 行为经济学是一种行为经济学.
- 代谢疾病 代谢疾病
背景情况:
- 2型糖尿病 (T2DM) 是一种普遍的代谢疾病,需要持续管理.
- 数字干预越来越多地用于T2DM治疗.
- 行为经济学为有效的数字干预提供了对决策的洞察力.
研究的目的:
- 评估基于行为数字干预对T2DM患者的影响.
- 将数字干预与虚拟或物理激励与传统治疗进行比较.
- 评估对HbA1c的影响,血糖 (SMBG) 测试率的自我监测,自我有效性和医疗费用.
主要方法:
- 预期随机对照试验 (RCT) 从2023年4月至2024年12月.
- 三组:数字干预带有虚拟激励,数字干预带有物理激励和传统治疗.
- 数据收集包括HbA1c,体重,SMBG率,自我有效性以及基线和每月3个月的成本.
主要成果:
- N/A - 结果尚未在提供的摘要中提供.
结论:
- 这项研究代表了经济学和医学在T2DM中使用数字技术的新整合.
- 它解决了基于行为经济学的T2DM在线干预方面的差距.
- 该试验对T2DM管理具有重要的新性和社会价值.
更多相关视频
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: Biguanides and Glitazones